BioMérieux and Baxter International enter in an “Exclusive Distribution Pact” for their Acute Kidney Injury (AKI) Diagnostic test. The NEPHROCLEAR CCL14 test will be distributed in the United States as well as Europe.
According to the agreement, both bioMérieux and Baxter will share commercialization, while bioMérieux will oversee the regulatory approval process. According to a Intensive Care Medicine study, The NEPHROCLEAR CCL14 diagnostic test has been the most predictive of stage 3 AKI, which is considered the most severe form of AKI.
Acute Kidney Injury is a condition where the kidneys shut down which is often the result of infection, illness, or trauma. This particular condition has recently become a more common complication in hospitals and ICUs. The diagnostic test will be able to provide healthcare professionals the ability to diagnose adequate treatment.
“Baxter’s agreement with bioMérieux will allow us to introduce a new diagnostic offering to our Acute Therapies portfolio and offer clinicians a meaningful tool as they manage the complexities of AKI in their patients,” Reaz Rasul, general manager of Baxter’s Acute Therapies business, said in a release.